Monopar Therapeutics shares are trading higher after Rodman & Renshaw initiated coverage on the stock with a Buy rating and announced a price target of $50.
Portfolio Pulse from Benzinga Newsdesk
Monopar Therapeutics shares rose following Rodman & Renshaw's initiation of coverage with a Buy rating and a $50 price target.
October 11, 2024 | 4:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Monopar Therapeutics shares increased after Rodman & Renshaw initiated coverage with a Buy rating and set a price target of $50.
The initiation of coverage by Rodman & Renshaw with a Buy rating and a significant price target of $50 is likely to positively influence investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100